What did Barclays and Cowen do on February 26, 2026?

Barclays maintained **Overweight** and raised its price target to **$7** on February 26, 2026. TD Cowen reiterated a **Buy** the same day. Both notes were published on February 26, 2026 and signal continued analyst support.

How should I interpret the CCCC analyst rating for investors?

The CCCC analyst rating updates show supportive analyst views but do not change company fundamentals. Use ratings with cash runway, trial timelines, and recent results before making investment decisions.

Does Barclays’ $7 price target mean the stock will reach $7?

A price target is an analyst estimate, not a guarantee. Barclays’ **$7** target reflects valuation assumptions and potential upside, but market forces and trial outcomes can change that view.

What is Meyka’s view and grade for CCCC?

Meyka AI rates CCCC with a grade of **B**. This grade considers S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Grades are not guarantees and we are not financial advisors.

Analyst Ratings

Barclays Maintains Overweight on C4 Therapeutics (CCCC) Feb 26, 2026

ByDanny Kontos February 27, 2026

Barclays maintained an Overweight rating on C4 Therapeutics, Inc. (CCCC) and raised its price target to $7 on February 26, 2026. This CCCC analyst rating update also included TD Cowen reiterating a Buy the same day. Both notes were published on February 26, 2026, and reflect continued analyst interest in the company’s clinical pipeline. Investors should note the market cap of $197,872,905 and recent price moves that came alongside the updates. Meyka AI flags these actions as sector-relevant signals for clinical-stage biotech stocks.